- Home
- IGMS vs PRPL Comparison
IGMS vs PRPL Comparison
Compare IGMS & PRPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- PRPL
- Stock Information
- Founded
- IGMS 1993
- PRPL 2010
- Country
- IGMS United States
- PRPL United States
- Employees
- IGMS N/A
- PRPL N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- PRPL Home Furnishings
- Sector
- IGMS Health Care
- PRPL Consumer Discretionary
- Exchange
- IGMS Nasdaq
- PRPL Nasdaq
- Market Cap
- IGMS 82.1M
- PRPL 96.8M
- IPO Year
- IGMS 2019
- PRPL N/A
- Fundamental
- Price
- IGMS $1.13
- PRPL $0.81
- Analyst Decision
- IGMS Hold
- PRPL Hold
- Analyst Count
- IGMS 8
- PRPL 2
- Target Price
- IGMS $6.14
- PRPL $1.25
- AVG Volume (30 Days)
- IGMS 155.8K
- PRPL 1.0M
- Earning Date
- IGMS 05-20-2025
- PRPL 05-06-2025
- Dividend Yield
- IGMS N/A
- PRPL N/A
- EPS Growth
- IGMS N/A
- PRPL N/A
- EPS
- IGMS N/A
- PRPL N/A
- Revenue
- IGMS $2,679,000.00
- PRPL $472,015,000.00
- Revenue This Year
- IGMS $121.76
- PRPL N/A
- Revenue Next Year
- IGMS $46.83
- PRPL $5.62
- P/E Ratio
- IGMS N/A
- PRPL N/A
- Revenue Growth
- IGMS 25.77
- PRPL N/A
- 52 Week Low
- IGMS $0.92
- PRPL $0.56
- 52 Week High
- IGMS $22.50
- PRPL $1.59
- Technical
- Relative Strength Index (RSI)
- IGMS 39.53
- PRPL 62.06
- Support Level
- IGMS $1.11
- PRPL $0.63
- Resistance Level
- IGMS $1.40
- PRPL $0.97
- Average True Range (ATR)
- IGMS 0.11
- PRPL 0.07
- MACD
- IGMS -0.01
- PRPL 0.03
- Stochastic Oscillator
- IGMS 5.56
- PRPL 59.77
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.